tradingkey.logo

Novo Nordisk Announces Reduction In US List Price For Wegovy, Ozempic, Rybelsus

ReutersFeb 24, 2026 1:05 PM

- Novo Nordisk A/S NOVOb.CO:

  • NOVO NORDISK ANNOUNCES SIGNIFICANT REDUCTION IN US LIST PRICE FOR WEGOVY®, OZEMPIC®, AND RYBELSUS® (SEMAGLUTIDE MEDICINES), BUILDING ON CONTINUED EFFORTS TO EXPAND ACCESS

  • NEW, LOWER LIST PRICE OF $675 PER MONTH ACROSS WEGOVY(®), OZEMPIC(®), AND RYBELSUS(®), EFFECTIVE JANUARY 1, 2027

  • THESE CHANGES IN LIST PRICE DO NOT HAVE AN IMPACT ON DIRECT-TO-PATIENT, SELF-PAY PRICES

  • DECISION APPLIES TO ALL DOSES OF THESE MEDICINES

Further company coverage: [NOVOb.CO]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI